{"id":"placebo-syringes-of-enoxaparin","safety":{"commonSideEffects":[{"rate":"1-3%","effect":"Bleeding"},{"rate":"<1%","effect":"Thrombocytopenia"},{"rate":"5-10%","effect":"Injection site hematoma"},{"rate":"1-3%","effect":"Elevated transaminases"},{"rate":null,"effect":"Osteoporosis (with long-term use)"}]},"_chembl":{"chemblId":"CHEMBL1201476","moleculeType":"Oligosaccharide"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Enoxaparin binds to and potentiates antithrombin III, a natural anticoagulant, leading to inactivation of coagulation factors Xa and IIa. This prevents thrombin generation and fibrin clot formation. It is administered subcutaneously and has more predictable pharmacokinetics than unfractionated heparin, making it suitable for both treatment and prophylaxis of thromboembolism.","oneSentence":"Enoxaparin is a low-molecular-weight heparin that inhibits blood clotting by enhancing the activity of antithrombin III against factors Xa and IIa.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:28:34.439Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prophylaxis of venous thromboembolism in surgical patients"},{"name":"Treatment of acute deep vein thrombosis"},{"name":"Treatment of acute pulmonary embolism"},{"name":"Prophylaxis in medically ill patients at risk of thromboembolism"}]},"trialDetails":[{"nctId":"NCT03664180","phase":"PHASE4","title":"Comparison of Anticoagulation Prolongation vs. no Anticoagulation in STEMI Patients After Primary PCI","status":"COMPLETED","sponsor":"Beijing Anzhen Hospital","startDate":"2019-01-11","conditions":"STEMI - ST Elevation Myocardial Infarction","enrollment":2989},{"nctId":"NCT02379806","phase":"PHASE3","title":"The SYMPTOMS - SYstematic Elderly Medical Patients Thromboprophylaxis: Efficacy on Symptomatic OutcoMeS - Study","status":"COMPLETED","sponsor":"University Hospital, Brest","startDate":"2015-09-03","conditions":"Venous Thromboembolism","enrollment":2560},{"nctId":"NCT04558125","phase":"PHASE4","title":"Low-Dose Tenecteplase in Covid-19 Diagnosed With Pulmonary Embolism","status":"TERMINATED","sponsor":"Cedars-Sinai Medical Center","startDate":"2020-09-08","conditions":"Pulmonary Embolism, COVID","enrollment":2},{"nctId":"NCT03841396","phase":"PHASE4","title":"A Study Comparing the Local Tolerability of Two Subcutaneous Heparins in Healthy Volunteers.","status":"COMPLETED","sponsor":"Aspen Global Incorporated","startDate":"2016-06-02","conditions":"Injection Site Reaction","enrollment":15},{"nctId":"NCT02401594","phase":"PHASE3","title":"PROphylaxis in NOn Major Orthopaedic Surgery","status":"TERMINATED","sponsor":"Centre Hospitalier Universitaire de Saint Etienne","startDate":"2015-12-08","conditions":"Non-major Orthopaedic Surgery","enrollment":3608},{"nctId":"NCT00345618","phase":"PHASE3","title":"Clinical Study Assessing Idrabiotaparinux Sodium Injections Once-weekly in Pulmonary Embolism Therapeutic Approach","status":"COMPLETED","sponsor":"Sanofi","startDate":"2006-06","conditions":"Embolism, Thrombosis","enrollment":3202},{"nctId":"NCT00371683","phase":"PHASE3","title":"Study of Apixaban for the Prevention of Thrombosis-related Events Following Knee Replacement Surgery","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2006-11","conditions":"Deep Vein Thrombosis, Pulmonary Embolism","enrollment":3608},{"nctId":"NCT00457002","phase":"PHASE3","title":"Study of Apixaban for the Prevention of Thrombosis-related Events in Patients With Acute Medical Illness","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2007-06","conditions":"Venous Thrombosis, Pulmonary Embolism","enrollment":6758},{"nctId":"NCT00362232","phase":"PHASE3","title":"Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Vein Thromboembolism (DVT) and Pulmonary Embolism (PE). A Study of BAY59-7939 in the Prevention of Venous Thrombo Embolism (VTE) in Subjects Undergoing Elective Total Knee Replacement.","status":"COMPLETED","sponsor":"Bayer","startDate":"2006-06","conditions":"Venous Thromboembolism","enrollment":3148},{"nctId":"NCT00396786","phase":"PHASE2","title":"Dose-ranging Study of Once-daily Regimen of BAY 59-7939 in the Prevention of VTE in Patients Undergoing Elective Total Hip Replacement","status":"COMPLETED","sponsor":"Bayer","startDate":"2004-11","conditions":"Venous Thromboembolism","enrollment":877},{"nctId":"NCT00679588","phase":"PHASE3","title":"Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Major Abdominal Surgery","status":"COMPLETED","sponsor":"Sanofi","startDate":"2008-04","conditions":"Venous Thromboembolism","enrollment":4413},{"nctId":"NCT00721760","phase":"PHASE3","title":"Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Hip Fracture Surgery","status":"COMPLETED","sponsor":"Sanofi","startDate":"2008-07","conditions":"Venous Thromboembolism","enrollment":1003},{"nctId":"NCT00697099","phase":"PHASE3","title":"Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Total Hip Replacement Surgery","status":"COMPLETED","sponsor":"Sanofi","startDate":"2008-06","conditions":"Venous Thromboembolism","enrollment":2326},{"nctId":"NCT00718224","phase":"PHASE3","title":"Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Elective Knee Replacement Surgery","status":"COMPLETED","sponsor":"Sanofi","startDate":"2008-07","conditions":"Venous Thromboembolism","enrollment":1150},{"nctId":"NCT00331838","phase":"PHASE2","title":"Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Knee Replacement Surgery","status":"COMPLETED","sponsor":"Sanofi","startDate":"2006-05","conditions":"Venous Thromboembolism","enrollment":705}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo: syringes of Enoxaparin","genericName":"Placebo: syringes of Enoxaparin","companyName":"Bayer","companyId":"bayer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Enoxaparin is a low-molecular-weight heparin that inhibits blood clotting by enhancing the activity of antithrombin III against factors Xa and IIa. Used for Prophylaxis of venous thromboembolism in surgical patients, Treatment of acute deep vein thrombosis, Treatment of acute pulmonary embolism.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}